HPB & Spleen · 8 April 2026

Critical Margin Assessment in Pancreatic Cancer Surgery

Surgeons must prioritize evaluating specific resection margins in pancreatic cancer for better patient outcomes.

Three key margins—superior-mesenteric vein (HR 1.48), medial (HR 1.92), and posterior (HR 1.65)—are significantly linked to disease-free survival.
R1 status worsens survival in gemcitabine-treated patients (HR 1.97) but not with mFOLFOXIRI.

Aim for thorough margin assessment focusing on these three areas to enhance surgical decision-making and patient prognoses.

Randomized Controlled Trial by Lambert A, Salleron J (…) Conroy T et 8 al. in Ann Surg

read the whole article in Ann Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

The latest stitches

HPB & Spleen3 Nov 2026

Liver cancer drugs around surgery remain unproven

Drugs given around liver cancer surgery have mostly failed, but one recent trial showed a real benefit.

Ann Surg Oncol2 Nov 2026

Pancreatic ductoscopy guides tissue preservation

In two older patients having robotic surgery for a pancreatic growth, ductoscopy and checks of the cut edge let surgeons leave the remaining pancreas in place.

HPB & Spleen30 Oct 2026

Intrahepatic cholangiocarcinoma has more options

Resection remains central, but care now includes preoperative therapy, liver-directed treatments and drugs matched to tumor changes.

All papers in HPB & Spleen →